RE:RE:RE:GSK drops the development of engineered cell therapyNovember 01, 2022 - GSK's looming Zantac lawsuits raise doubts on the company's immediate M&A activities - as Wolfe Research analyst Tim Anderson suggested during a separate earnings call with investors. The uncertainty around the Zantac lawsuits means GSK might have to reserve money to resolve the legal liabilities. That could mean a temporary hold on dealmaking, especially mergers and acquisitions, Anderson argued.
https://www.fiercepharma.com/pharma/gsks-shingrix-rebound-rolls-record-sales-looming-zantac-lawsuits-raise-ma-doubt
[ This development limits the possibilities of partnerships for GSK's PD-1 immune checkpoint inhibitor Jemperli, which is an anti-PD-1 therapy for recurrent or advanced endometrial cancer approved in the United States and Canada, as a monotherapy for adult patients with mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer, that has progressed on or following prior treatment with a platinum containing regimen.]
https://ca.gsk.com/en-ca/media/press-releases/gsk-s-jemperli-dostarlimab-for-injection-approved-in-canada-as-an-anti-pd-1-therapy-for-recurrent-or-advanced-endometrial-cancer/
https://www.gsk.com/en-gb/media/press-releases/gsk-receives-fda-accelerated-approval-for-jemperli-dostarlimab-gxly-for-adult-patients-with-mismatch-repair-deficient-dmmr-recurrent-or-advanced-solid-tumours/